The two-day certification program is sponsored by ISSCA, will feature three topics new to the group’s Colombian training circuit

MIAMI LAKES, Florida— The International Society for Stem Cell Application (ISSCA), a global leader in stem cells research, applications, and education, has announced their latest certification program to be held in Bogota, Colombia on March 13-14, 2020.

The Stem Cells Certification course will feature a number of educational and hands-on sessions designed to give physicians the tools needed to integrate regenerative treatments into their practices. Registration for the two-day course is limited to eight participants to allow for intensive training and interaction.

During the two-day training, ISSCA faculty will share the latest stem cell protocols, including how to harvest and process stem cells derived from Stromal Vascular Faction (SVF) tissue and bone marrow. 

ISSCA faculty will additionally introduce three new protocols never before covered in past courses held in Colombia. The new curriculum includes clinical applications of allogeneic stem cells; using GCell technology, a device that can process SVF without enzymatic compounds; and an introduction to NK cell protocols, the newest regenerative medicine treatment to fight cancer.

“Our two-day training in Bogota will provide physicians with an invaluable opportunity to receive intensive hands-on training and education in some of today’s most effective and cutting-edge stem cells protocols,” said Benito Novas, ISSCA VP of Public Relations. “Physicians will learn from global leaders in the stem cells industry and be able to take practical application strategies back with them to integrate into their own practices to help patients suffering from degenerative diseases.”To learn more about the ISSCA, visit  www.issca.us.  More information about the Bogota certification course can be found at http://cursocelulasmadre.com/entrenamiento-bogota-programa/

The two-day certification program is sponsored by ISSCA, will feature three topics new to the group’s Colombian training circuit

MIAMI LAKES, Florida— The International Society for Stem Cell Application (ISSCA), a global leader in stem cells research, applications, and education, has announced their latest certification program to be held in Bogota, Colombia on March 13-14, 2020.

The Stem Cells Certification course will feature a number of educational and hands-on sessions designed to give physicians the tools needed to integrate regenerative treatments into their practices. Registration for the two-day course is limited to eight participants to allow for intensive training and interaction.

During the two-day training, ISSCA faculty will share the latest stem cell protocols, including how to harvest and process stem cells derived from Stromal Vascular Faction (SVF) tissue and bone marrow. 

ISSCA faculty will additionally introduce three new protocols never before covered in past courses held in Colombia. The new curriculum includes clinical applications of allogeneic stem cells; using GCell technology, a device that can process SVF without enzymatic compounds; and an introduction to NK cell protocols, the newest regenerative medicine treatment to fight cancer.

“Our two-day training in Bogota will provide physicians with an invaluable opportunity to receive intensive hands-on training and education in some of today’s most effective and cutting-edge stem cells protocols,” said Benito Novas, ISSCA VP of Public Relations. “Physicians will learn from global leaders in the stem cells industry and be able to take practical application strategies back with them to integrate into their own practices to help patients suffering from degenerative diseases.”To learn more about the ISSCA, visit  www.issca.us.  More information about the Bogota certification course can be found at http://cursocelulasmadre.com/entrenamiento-bogota-programa/

The group is set to sponsor the 2nd Congress of Aesthetic Medicine and Regenerative Gynecology to be held in Paraguay 
MIAMI LAKES, Florida—The Global Stem Cells Group (GSCG) has announced its sponsorship of the 2nd Congress of Aesthetic Medicine and Regenerative Gynecology to be held on March 12-13, 2020 in Asuncion, Paraguay. The GSCG’s CEO Benito Novas and Development and Research Director Dra. Maritza Novas will each deliver key lectures during the annual medical congress, which will focus on advancements in the fields of aesthetic medicine and regenerative gynecology. 
Benito Novas serves as the GSCG’s CEO and will lead a lecture on regenerative medicine marketing strategies. His talk will give practical marketing tools and advice to physicians running their own private practices in aesthetic medicine. In addition to his role as CEO with the GSCG, Novas also serves as the Head of Public Relations for the International Society for Stem Cell Application (ISSCA) and has authored two books on marketing strategies for clinics in the regenerative medicine industry, Your Aesthetic Practice: What Your Patients Are Saying and Marketing Digital en Su Clínica Estética (https://www.thriftbooks.com/a/benito-novas/2752773/). 
Dra. Maritza Novas serves as the GSCG’s Development and Research Director as well as the US Director for the ISSCA. She will deliver the opening lecture for the congress, discussing clinical applications of regenerative medicine in the aesthetic field. Her lecture will be informed by clinical case studies demonstrating the efficacy of regenerative treatments in aesthetics. Dra. Novas is well-renowned in the field of regenerative medicine for making a profound impact on her patients through innovative treatment protocols. She has additionally trained countless doctors looking to add regenerative medicine to their practices.  
On March 14, following the conclusion of the congress, representatives from the GSCG will also offer a certification course in cellular therapy. The course is designed to help all physicians who want to add stem cells therapies based on birth tissue derived components to their practices. Attendees will learn about the latest stem cell products, such as exosomes, cord blood, and amniotic fluid. Additional topics to be covered will include how to choose the right products to treat specific conditions and details about how to handle the manufacturing process, from selecting a healthy donor through quality control and storage at the medical office. 
“The Global Stem Cells Group is pleased to serve as a sponsor for the 2nd Congress of Aesthetic Medicine and Regenerative Gynecology,” said Benito Novas. “We look forward to sharing today’s best research on marketing strategies to help regenerative medicine practices grow their success and influence as well as sharing clinical applications of stem cells treatments in aesthetic medicine. As a global leader in stem cells education, we always look forward to these events to help more physicians gain the knowledge and skills necessary to bring life-saving treatments to more patients across the globe.”  
To learn more about the Global Stem Cells Group and all of the group’s latest news and innovations, visit  http://www.stemcellsgroup.com/.

The group is set to sponsor the 2nd Congress of Aesthetic Medicine and Regenerative Gynecology to be held in Paraguay 
MIAMI LAKES, Florida—The Global Stem Cells Group (GSCG) has announced its sponsorship of the 2nd Congress of Aesthetic Medicine and Regenerative Gynecology to be held on March 12-13, 2020 in Asuncion, Paraguay. The GSCG’s CEO Benito Novas and Development and Research Director Dra. Maritza Novas will each deliver key lectures during the annual medical congress, which will focus on advancements in the fields of aesthetic medicine and regenerative gynecology. 
Benito Novas serves as the GSCG’s CEO and will lead a lecture on regenerative medicine marketing strategies. His talk will give practical marketing tools and advice to physicians running their own private practices in aesthetic medicine. In addition to his role as CEO with the GSCG, Novas also serves as the Head of Public Relations for the International Society for Stem Cell Application (ISSCA) and has authored two books on marketing strategies for clinics in the regenerative medicine industry, Your Aesthetic Practice: What Your Patients Are Saying and Marketing Digital en Su Clínica Estética (https://www.thriftbooks.com/a/benito-novas/2752773/). 
Dra. Maritza Novas serves as the GSCG’s Development and Research Director as well as the US Director for the ISSCA. She will deliver the opening lecture for the congress, discussing clinical applications of regenerative medicine in the aesthetic field. Her lecture will be informed by clinical case studies demonstrating the efficacy of regenerative treatments in aesthetics. Dra. Novas is well-renowned in the field of regenerative medicine for making a profound impact on her patients through innovative treatment protocols. She has additionally trained countless doctors looking to add regenerative medicine to their practices.  
On March 14, following the conclusion of the congress, representatives from the GSCG will also offer a certification course in cellular therapy. The course is designed to help all physicians who want to add stem cells therapies based on birth tissue derived components to their practices. Attendees will learn about the latest stem cell products, such as exosomes, cord blood, and amniotic fluid. Additional topics to be covered will include how to choose the right products to treat specific conditions and details about how to handle the manufacturing process, from selecting a healthy donor through quality control and storage at the medical office. 
“The Global Stem Cells Group is pleased to serve as a sponsor for the 2nd Congress of Aesthetic Medicine and Regenerative Gynecology,” said Benito Novas. “We look forward to sharing today’s best research on marketing strategies to help regenerative medicine practices grow their success and influence as well as sharing clinical applications of stem cells treatments in aesthetic medicine. As a global leader in stem cells education, we always look forward to these events to help more physicians gain the knowledge and skills necessary to bring life-saving treatments to more patients across the globe.”  
To learn more about the Global Stem Cells Group and all of the group’s latest news and innovations, visit  http://www.stemcellsgroup.com/.

The group will launch its innovative GCell technology and a new online course at the event, while CEO Benito Novas will lead a lecture about marketing in the regenerative medicine field 
MIAMI LAKES, Florida—The Global Stem Cells Group (GSCG) is set to sponsor the Second Intercontinental Medical Congress on Anti-Aging and Longevity (https://miami2020.semal.org/) hosted by the Spanish Society of Anti-Aging Medicine (SEMAL) and the Federation of Latin American of Anti-Aging Medicine (FISMAL). The congress will be held on February 6-9, 2020 in Miami, Florida at the Hampton Inn & Suites by Hilton Miami Brickell. 
During the event, the Global Medical Group, a subsidiary of GSCG, will launch its GCell micrograft technology, an autologous tissue suspension that boasts minimal manipulation. The product has application implications for a wide range of medical uses, including orthopedics, dermatology, cosmetic gynecology, aesthetics, and hair loss. 
GCell technology will allow physicians utilizing regenerative medicine to continue practicing adult stem cells-based procedures thanks to the product’s adherence to FDA compliance standards since the procedure does not utilize enzymes. 
GCell technology is a closed-system medical device that harnesses the natural and powerful restorative capabilities of adipose tissue. The GCell SVF (Stromal Vascular Fraction) procedure can be performed in office in around 30 minutes, while existing procedures can take up to two hours. It also utilizes only local anesthesia, and performing physicians only have to collect 15 ml of fat instead of the 50 ml required for traditional protocols.
During the congress, the GSCG will also be launching its new online stem cells course, which will benefit doctors interested in learning about the newest stem cells protocols and technologies. The course will specifically focus on stem cells protocols based on first tissue derived compounds, such as exosomes, cord blood, and amniotic fluid. 
In addition to launching GCell technology and its new course, the GSCG’s CEO and founder Benito Novas will be giving a lecture in the main room. He will be speaking to attendees about the newest challenges facing the regenerative medicine filed and what types of marketing strategies practitioners should implement to run a successful practice integrating regenerative medicine.  
“The Global Stem Cells Group is looking forward to attending the Second Intercontinental Medical Congress on Anti-Aging and Longevity to talk with attending physicians and researchers about the technological and educational advances we are making to help move the field of regenerative medicine forward,” said Novas. 
To learn more about the Global Stem Cells Group and all of the group’s latest news and innovations, visit  http://www.stemcellsgroup.com/.

The agreement between Global and CHU Mohammed VI in Marrakech will help enhance staff preparation and clinical offerings in regenerative medicine
MIAMI LAKES, Florida— Stem Cells Training Inc., a subsidiary of the Global Stem Cells Group (GSCG), has announced that it has signed an onsite training agreement with Centre Hospitalo-Universitaire Mohammed VI Marrakech (CHU). GSCG faculty will travel to Marrakech, Morocco to provide this invaluable two-day training to CHU’s staff on February 14 and 15, 2020. 
The agreement names the GSCG as CHU’s provider of training for the facility’s regenerative medicine staff. Through the deal, the GSCG will provide preparation and education in the latest regenerative medicine techniques and stem cells protocols, focusing on those utilizing adult stem cells and birth tissue derived from stem cells. In addition to on-site training, the agreement also names the GSCG as CHU’s provider for all necessary equipment to implement regenerative medicine treatments. 
The additional training and supplies offered through the agreement will allow CHU to incorporate the industry’s most effective stem cells protocols into the hospital’s treatment options. 
The Centre Hospitalo-Universitaire Mohammed VI is a regional leader in quality patient care, student education, physician training, and innovative medical research. Located in Marrakech, CHU provides the bustling city with short-, medium-, and long-range care solutions. Counted among its innovative institutional projects, CHU’s Culture and Health program is committed to making the hospital a more human environment for patients seeking care.
“The agreement between the Global Stem Cells Group and the Centre Hospitalo-Universitaire Mohammed VI Marrakech is an important one for both partners,” said Benito Novas, CEO of the Global Stem Cells Group. “As a university institution, CHU is interested in leading clinical trials to prove the safety and efficacy of regenerative medicine treatment protocols—something the GSCG has a vested interest in. This agreement will allow us to train hospital staff to offer cutting-edge treatments to patients in Morocco while helping stem cells treatments gain more traction globally, making them more viable options for physicians to incorporate into their practices.” 
With the newly signed agreement, the GSCG continues to advance its mission to expand its presence across the global, especially focusing on North America and the Middle East. Physicians looking to grow their practices by offering regenerative medicine treatments can benefit from the GSCG’s trainings, which are conveniently held onsite at physicians’ home facilities, no matter where they are located globally. 
To learn more about the onsite training opportunities offered by the Global Stem Cells Group, visit https://www.stemcelltraining.net/onsitetraining/. To learn more about the Centre Hospitalo-Universitaire Mohammed VI Marrakech, visit  www.chumarrakech.ma.

The agreement between Global and CHU Mohammed VI in Marrakech will help enhance staff preparation and clinical offerings in regenerative medicine
MIAMI LAKES, Florida— Stem Cells Training Inc., a subsidiary of the Global Stem Cells Group (GSCG), has announced that it has signed an onsite training agreement with Centre Hospitalo-Universitaire Mohammed VI Marrakech (CHU). GSCG faculty will travel to Marrakech, Morocco to provide this invaluable two-day training to CHU’s staff on February 14 and 15, 2020. 
The agreement names the GSCG as CHU’s provider of training for the facility’s regenerative medicine staff. Through the deal, the GSCG will provide preparation and education in the latest regenerative medicine techniques and stem cells protocols, focusing on those utilizing adult stem cells and birth tissue derived from stem cells. In addition to on-site training, the agreement also names the GSCG as CHU’s provider for all necessary equipment to implement regenerative medicine treatments. 
The additional training and supplies offered through the agreement will allow CHU to incorporate the industry’s most effective stem cells protocols into the hospital’s treatment options. 
The Centre Hospitalo-Universitaire Mohammed VI is a regional leader in quality patient care, student education, physician training, and innovative medical research. Located in Marrakech, CHU provides the bustling city with short-, medium-, and long-range care solutions. Counted among its innovative institutional projects, CHU’s Culture and Health program is committed to making the hospital a more human environment for patients seeking care.
“The agreement between the Global Stem Cells Group and the Centre Hospitalo-Universitaire Mohammed VI Marrakech is an important one for both partners,” said Benito Novas, CEO of the Global Stem Cells Group. “As a university institution, CHU is interested in leading clinical trials to prove the safety and efficacy of regenerative medicine treatment protocols—something the GSCG has a vested interest in. This agreement will allow us to train hospital staff to offer cutting-edge treatments to patients in Morocco while helping stem cells treatments gain more traction globally, making them more viable options for physicians to incorporate into their practices.” 
With the newly signed agreement, the GSCG continues to advance its mission to expand its presence across the global, especially focusing on North America and the Middle East. Physicians looking to grow their practices by offering regenerative medicine treatments can benefit from the GSCG’s trainings, which are conveniently held onsite at physicians’ home facilities, no matter where they are located globally. 
To learn more about the onsite training opportunities offered by the Global Stem Cells Group, visit https://www.stemcelltraining.net/onsitetraining/. To learn more about the Centre Hospitalo-Universitaire Mohammed VI Marrakech, visit  www.chumarrakech.ma.